Sensei Biotherapeutics (SNSE) Competitors

$1.53
-0.06 (-3.77%)
(As of 05/17/2024 ET)

SNSE vs. PMN, MRKR, CARA, LEXX, XLO, UNCY, SPRB, FBIO, VYNE, and BCTX

Should you be buying Sensei Biotherapeutics stock or one of its competitors? The main competitors of Sensei Biotherapeutics include ProMIS Neurosciences (PMN), Marker Therapeutics (MRKR), Cara Therapeutics (CARA), Lexaria Bioscience (LEXX), Xilio Therapeutics (XLO), Unicycive Therapeutics (UNCY), Spruce Biosciences (SPRB), Fortress Biotech (FBIO), VYNE Therapeutics (VYNE), and BriaCell Therapeutics (BCTX). These companies are all part of the "pharmaceutical preparations" industry.

Sensei Biotherapeutics vs.

Sensei Biotherapeutics (NASDAQ:SNSE) and ProMIS Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, community ranking, dividends, profitability and media sentiment.

Sensei Biotherapeutics received 21 more outperform votes than ProMIS Neurosciences when rated by MarketBeat users. However, 100.00% of users gave ProMIS Neurosciences an outperform vote while only 76.67% of users gave Sensei Biotherapeutics an outperform vote.

CompanyUnderperformOutperform
Sensei BiotherapeuticsOutperform Votes
23
76.67%
Underperform Votes
7
23.33%
ProMIS NeurosciencesOutperform Votes
2
100.00%
Underperform Votes
No Votes

Sensei Biotherapeutics' return on equity of -46.67% beat ProMIS Neurosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Sensei BiotherapeuticsN/A -46.67% -40.88%
ProMIS Neurosciences N/A -2,311.60%-130.13%

In the previous week, Sensei Biotherapeutics and Sensei Biotherapeutics both had 4 articles in the media. ProMIS Neurosciences' average media sentiment score of 0.61 beat Sensei Biotherapeutics' score of 0.43 indicating that ProMIS Neurosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sensei Biotherapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
ProMIS Neurosciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Sensei Biotherapeutics has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Comparatively, ProMIS Neurosciences has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.

ProMIS Neurosciences has higher revenue and earnings than Sensei Biotherapeutics. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sensei BiotherapeuticsN/AN/A-$34.10M-$1.21-1.26
ProMIS Neurosciences$10K3,498.12-$13.21M-$0.74-2.49

10.5% of Sensei Biotherapeutics shares are held by institutional investors. Comparatively, 50.1% of ProMIS Neurosciences shares are held by institutional investors. 25.5% of Sensei Biotherapeutics shares are held by insiders. Comparatively, 10.3% of ProMIS Neurosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Sensei Biotherapeutics presently has a consensus price target of $4.50, indicating a potential upside of 194.12%. ProMIS Neurosciences has a consensus price target of $8.00, indicating a potential upside of 333.60%. Given ProMIS Neurosciences' higher probable upside, analysts plainly believe ProMIS Neurosciences is more favorable than Sensei Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sensei Biotherapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
ProMIS Neurosciences
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

ProMIS Neurosciences beats Sensei Biotherapeutics on 8 of the 13 factors compared between the two stocks.

Get Sensei Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SNSE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SNSE vs. The Competition

MetricSensei BiotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$38.37M$6.78B$5.23B$7.98B
Dividend YieldN/A2.72%44.24%3.91%
P/E Ratio-1.2613.88119.9616.67
Price / SalesN/A316.172,373.9285.85
Price / CashN/A34.4236.8831.98
Price / Book0.665.795.504.64
Net Income-$34.10M$138.82M$105.95M$217.28M
7 Day Performance1.32%1.45%1.42%2.90%
1 Month Performance57.73%4.81%4.96%6.66%
1 Year Performance2.00%-3.83%7.89%9.89%

Sensei Biotherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PMN
ProMIS Neurosciences
3.1144 of 5 stars
$1.96
-2.0%
$8.00
+308.2%
-66.9%$37.16M$10,000.00-1.736Earnings Report
Upcoming Earnings
Gap Down
MRKR
Marker Therapeutics
4.0771 of 5 stars
$3.98
-2.7%
$11.00
+176.4%
+212.0%$36.46M$3.31M0.008Upcoming Earnings
CARA
Cara Therapeutics
3.5278 of 5 stars
$0.72
-4.0%
$9.75
+1,247.4%
-80.5%$39.56M$20.97M-0.3355Analyst Forecast
Analyst Revision
LEXX
Lexaria Bioscience
2.3521 of 5 stars
$3.08
-3.1%
$12.00
+289.6%
+256.6%$39.70M$230,000.00-4.535News Coverage
XLO
Xilio Therapeutics
0.2484 of 5 stars
$1.09
-2.7%
N/A-63.7%$40.23MN/A-0.3973Gap Down
UNCY
Unicycive Therapeutics
2.1095 of 5 stars
$1.09
flat
$5.30
+386.2%
-25.2%$41.00M$680,000.00-0.7012Upcoming Earnings
Analyst Forecast
Analyst Revision
SPRB
Spruce Biosciences
3.5344 of 5 stars
$0.82
+2.5%
$5.67
+587.0%
-66.8%$33.94M$10.09M-0.6629Analyst Forecast
Analyst Revision
News Coverage
Gap Down
FBIO
Fortress Biotech
2.4709 of 5 stars
$1.76
+3.5%
$30.00
+1,604.5%
-74.9%$33.86M$84.51M-0.21187Analyst Forecast
News Coverage
VYNE
VYNE Therapeutics
3.5752 of 5 stars
$2.89
+2.1%
$5.75
+99.0%
-59.1%$41.99M$420,000.00-0.5310
BCTX
BriaCell Therapeutics
1.1803 of 5 stars
$2.11
-5.4%
$18.00
+753.1%
-76.4%$33.72MN/A-1.2616News Coverage
Gap Up

Related Companies and Tools

This page (NASDAQ:SNSE) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners